Department of Geriatrics and Palliative Medicine, Mount Sinai School of Medicine, New York, New York.
Pediatrics. 2016 Mar;137(3):e20154467. doi: 10.1542/peds.2015-4467. Epub 2016 Feb 8.
This article describes the update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents.
The USPSTF reviewed the evidence on the benefits and harms of screening, accuracy of primary care-feasible screening tests, and benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years.
This recommendation applies to children and adolescents aged ≤18 years who do not have an MDD diagnosis.
The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged ≤11 years (I statement).
本文介绍了对 2009 年美国预防服务工作组（USPSTF）关于儿童和青少年重度抑郁症（MDD）筛查建议的更新。
USPSTF 回顾了筛查的益处和危害、初级保健可行的筛查测试的准确性以及心理治疗、药物治疗和协作式护理模式对 7 至 18 岁患者的益处和危害的证据。
本建议适用于≤18 岁无 MDD 诊断的儿童和青少年。
USPSTF 建议对 12 至 18 岁的青少年进行 MDD 筛查。应建立适当的系统来实施筛查，以确保准确的诊断、有效的治疗和适当的随访（B 级推荐）。USPSTF 得出结论，目前的证据不足以评估对≤11 岁儿童 MDD 筛查的利弊平衡（I 声明）。
